Cells engage sophisticated programs of DNA damage response (DDR) and repair to guard against genetic mutations. Although there is significant knowledge concerning DDR in interphase cells, much less is known about these processes in mitosis. Direct interaction between MDC1, a master DDR organizer, and a marker of DNA damage, histone gH2AX, is required to trigger robust repair. Here we show that the DNA damage-induced interaction between MDC1 and gH2AX is attenuated in mitosis. Furthermore, inhibition in the activity of the core mitotic regulator CDK1, either by pharmacologic inhibition or siRNA attenuation, enhances MDC1-gH2AX colocalization in mitosis. Our findings offer key new insights into how DDR is controlled during mitosis. Cancer Res; 72(21); 5448-53. Ó2012 AACR.
Introduction
Among various types of DNA damage, the DNA double strand break (DSB) is the most detrimental type, as no intact strand is left as a template for repair unless cell processes duplicate genomic material during proliferation. Eukaryotic cells have evolved an intricate DNA damage response (DDR) system to ensure the error-free duplication and separation of genomic information during the cell cycle. A primary sensor for DSB is H2AX, a variant of histone H2A, which is a component of the nucleosome (1) . Upon DSB, the MRE11-RAD50-NBS1 (MRN) complex recognizes free ends of DNA and recruits activated ataxia telangiectasia-mutated to phosphorylate H2AX on Serine 139. This phosphorylated H2AX, termed gH2AX, directly interacts with an adaptor protein, mediator of DNA damage checkpoint 1 (MDC1), to initiate a cascade of DDR, amplifying and transducing the signal to downstream effectors to induce cell cycle arrest and DNA repair (2) . Alternatively, cells can undergo apoptosis or permanent senescence to prevent the propagation of mutated daughter cells (3) .
One hallmark of DDR is the accumulation and retention of repair proteins, which form microscopically discernible foci at the lesion sites. Such foci formation is hierarchic and depends on direct interaction between upstream and downstream factors (4) . Over the past decade, extensive studies have generated a wealth of information on the mechanism of DDR in interphase cells; however, the precise mechanism regulating DDR during mitosis has yet to be unveiled. Previously, our lab has reported mitotic arrest as a novel source of DSBs (5) . We hypothesize that the increase in DSBs during prolonged mitosis is due to lack of adequate DDR and accumulation of spontaneous inherent DNA damage. Supporting our hypothesis, recent research suggests an interesting model of incomplete mitotic DDR, wherein lesions are marked but downstream DDR is delayed until after mitotic exit (6). Accordingly, major mitotic kinases have been shown to actively inhibit DNA damage checkpoints (7) . In particular, cyclin-dependent kinase 1 (CDK1) exhibits inhibitory effects on DSB repair shown in yeast and cell-free Xenopus laevis systems (8, 9) . However, how the master organizer MDC1 is regulated during mitosis is unknown. On the one hand, MDC1 colocalizes with gH2AX in human osteosarcoma U2OS cell line after g-irradiation (6). On the other hand, MDC1 physically binds to anaphase-promoting complex/cyclosome (APC/C) complex and promote activation thereof (10) . Consistently, siRNA downregulation of MDC1 blocks metaphase-anaphase transition (11) . The dual role of MDC1 in mitosis indicates an unknown regulator. Here, we report that CDK1 activity reduces MDC1-gH2AX interaction during mitosis.
Materials and Methods

Cell culture and treatments
All cell lines were obtained from American Type Culture Collection and authenticated by short tandem repeat profiling. Early passage cells were used for experimentation and maintained in McCoy's 5A Medium, supplemented with 1% penicillin-streptomycin and 10% FBS. Nocodazole and RO3306 were used at 200 nmol/L and 2 mmol/L, respectively. g-irradiation was done in a Cs-137 Gamma cell. CDK1 knockdowns were carried out using Stealth Select siRNA by RNAiMax transfection (Life Technologies). Final concentration of siRNA oligonucleotides was 20 nmol/L. All analyses and further treatments were done 48-hour posttransfection.
Immunofluorescent staining
Cells received 2 Gy of g-irradiation and recovered for 30 m before fixation with 2% formaldehyde/PBS at room temperature (RT), washed and blocked with staining buffer (3% BSA, Triton X-100 in PBS). Samples were incubated with primary and secondary antibodies for 1 hour each at RT before Hoechst counterstaining. Confocal microscopy images were taken from Zeiss LSM Meta 510.
Immunoprecipitation
For coimmunoprecipitation, lysates were prepared with Nuclear Complex Co-IP Kit (Active Motif) with minor modifications. For denaturing immunoprecipitation, whole cell extracts were denatured by boiling in denaturing buffer before immunoprecipitation.
Results and Discussion
Considering that foci formation is required for efficient repair of DSB, we first examined MDC1-gH2AX colocalization patterns in various phases of mitosis. Asynchronous HCT116 were subjected to 2 Gy of g-irradiation, which efficiently induced DSBs without preventing mitosis (12) . In contrast to the formation of distinct foci in interphase and anaphase cells, there was a progressive loss of colocalization of MDC1 with gH2AX during prometaphase and metaphase, as evidenced by the increased diffuse immunostaining of MDC1 (Fig. 1A) . The colocalized MDC1-gH2AX foci returned upon commencement of anaphase. The distinct localization pattern of MDC1 coincided with dynamics of CDK1 activity, which reaches its peak in late prophase and declines in anaphase (13) . The relatively short time frame in which the MDC1 foci reappeared in anaphase suggests that their formation is posttranslationally regulated.
To confirm such colocalization indeed decreases in prometaphase, we introduced prometaphase block by nocodazole treatment and investigated MDC1-gH2AX colocalization. Consistently, MDC1 failed to colocalize with gH2AX in mitotically arrested cells ( Fig. 1B; 16 hours), whereas such colocalization was restored in postmitotic cells ( Fig. 1B ; 40 hours). We also collected cells from the corresponding time points and measured MDC1 protein levels, which were not decreased in cells arrested in mitosis at 16 hours (Fig 1C;  Supplementary Fig. S1 ). These observations suggest that the decreased colocalization of MDC1-gH2AX occurs in prometaphase and is likely due to posttranslational modification of MDC1.
To confirm results of the morphologic study, we biochemically determined the affinity between MDC1 and gH2AX in mitotic cells. HT29 cells were synchronized in mitosis by nocodazole treatment before g-irradiation and shake off, that latter successfully separated mitotic cells from interphase cells that remained attached ( Fig. 2A) . The purity of the mitotic population was confirmed by FACS analysis (Supplementary Fig. S2 ). We then immunoprecipitated the H2AX immune complexes with a pan-H2AX antibody, which does not abrogate MDC1-gH2AX binding. Compared with attached cells (Fig. 2B ; lanes 4 and 6), significantly less amount of MDC1 was immunoprecipitated with gH2AX in mitotic cells ( Fig. 2B; lanes 3 and 5) . This result shows that the recruitment of MDC1 to gH2AX is reduced in prometaphase cells, independent of additional g-irradiation. Furthermore, MDC1 in mitotic cells exhibited retarded mobility upon gel electrophoresis ( Fig. 2B ; lane 3 and 5, input), suggesting that posttranslational modification weakened MDC1-gH2AX interaction. This observation is in agreement with a previous report showing a reduction of MDC1 pull-down by a gH2AX peptide from mitotic cell lysates compared with nonmitotic cell lysates (6) . This decrease of MDC1-gH2AX interaction is also consistent with the finding that APC/C and gH2AX binds to the same MDC1 domain, providing a model of competitive binding to MDC1 between APC/C components and gH2AX (10). Functionally speaking, MDC1 is required for metaphase-anaphase transition through APC/C activation during normal mitosis (11) . Taken together, these observations provide an explanation for reduced MDC1-gH2AX interaction in mitosis, indicating that the role of MDC1, as a mitotic regulator, precedes that of a DDR mediator. Specifically, modified MDC1 dissociates from DSB sites in order for timely APC/C activation and weakens mitotic DDR due to insufficient bound MDC1.
Next we sought to identify the regulator(s) of MDC1 localization in mitosis. Previous studies reveal that phosphorylation is a major mechanism of MDC1 regulation (14) . Because CDK1 is the definitive mitotic kinase (15), we tested whether MDC1 was phosphorylated by CDK1 in mitosis. We synchronized HCT116 cells in mitosis by nocodazole treatment for 16 hours. The CDK1 inhibitor RO3306 was included as a negative control. To exclude contaminating proteins binding to MDC1, we denatured whole cell extracts before immunoprecipitating with an MDC1 antibody. We then used an MPM2 antibody to detect phosphorylation on CDK1 motif (s) in immunoprecipitated MDC1 protein. As shown in Fig. 2C , mitotic cells had a higher level of MPM2 reactivity than asynchronous cell population. Consistently, CDK1 inhibition reduced both MPM2 abundance and mitotic index to the baseline ( Fig. 2C; Supplementary Fig. S3 ). Our result is consistent with the mitotic phosphoproteomics study, suggesting CDK1 as the candidate kinase of MDC1 in mitosis (16) .
Having established that CDK1 as the putative kinase regulating MDC1, we examined the effect of CDK1 inhibition on MDC1-gH2AX colocalization in mitotic cells. Unlike other CDK1/CDK2 dual inhibitors, RO3306 exhibits a 10-fold selectivity for CDK1 over CDK2 (17) . As shown in Fig. 3A , RO3306-treated HCT116 cells showed a significant increase in MDC1-gH2AX colocalization in prometaphase and metaphase, judging by the intensified MDC1 foci compared with control cells. A similar effect was observed in HCT116 cells at a higher irradiation dosage (10 Gy; Supplementary Fig. S4 ). We also conducted the experiment in HT29 cells, which are proficient in mismatch repair in contrast to HCT116 (18) , and showed that CDK1 inhibition too strengthened MDC1-gH2AX colocalization in mitotic cells (Supplementary Fig. S5 ). Furthermore, we tested whether CDK1 inhibition could enhance MDC1-gH2AX colocalization in prometaphase-blocked HCT116 (Fig. 3B) . Indeed, additional treatment with RO3306 restored the colocalization compared with nocodazole treatment alone (Fig. 3C ). These findings indicate that CDK1 activity induces the loss of MDC1-gH2AX interaction during mitosis.
Finally, to confirm the result of pharmacologic studies, we used siRNA to downregulate CDK1 in HCT116 cells. CDK1 was effectively knocked down ( Supplementary Fig. S6 ), although the remaining CDK1 protein was sufficient for cell division according to nuclear morphology. Consistently, CDK1 knockdown significantly enhanced MDC1-gH2AX colocalization in prometaphase and metaphase cells compared with control siRNA treatment (Fig. 4A) . To test whether low CDK1 activity protects MDC1-gH2AX colocalization in prolonged mitosis, we knocked down CDK1 before nocodazole treatment (Fig.  4B) . Interestingly, sustained low CDK1 activity protected MDC1-gH2AX colocalization even when prometaphase was prolonged (Fig. 4C) . These data suggest that MDC1 foci disassembly requires a higher CDK1 activity threshold than that necessary for the maintenance of mitosis.
In this study, we showed that MDC1-gH2AX interaction decreases as a cell traverses through two critical phases of mitosis, prometaphase and metaphase. This observation suggests that MDC1-gH2AX interaction is inversely correlated with CDK1 activity. Simona Giunta et al. reported that MDC1 colocalized with gH2AX in U2OS cells during normal mitosis (6) . Although our results do not completely agree with theirs, we did observe residual MDC1 foci in prometaphase in the colon cancer cells we used. This discrepancy could be due to that duration of normal prometaphase is not sufficient for a complete MDC1 foci disassembly, shown as smaller foci accompanied with increased diffuse immunostaining. Supporting this idea, we observed that prometaphase block by nocodazole could further diminish MDC1-gH2AX colocalization. This suggests MDC1 foci disassembly starts at prometaphase, presumably due to the maximized CDK1 activity. Moreover, CDK1 activity reduction, by either pharmacologic or genetic manipulation, restored MDC1-gH2AX colocalization in both normal and prolonged mitosis. These data suggest that high CDK1 activity constitutively promotes MDC1 foci disassembly. However, whether phosphorylation of MDC1 by CDK1 induces foci disassembly requires further elucidation. Recently, Zhang et al. reported that high CDK1 activity suppressed mitotic DDR (19) . Although we agree with their overarching hypothesis, the usage of alsterpaullone, a nonspecific CDK1 inhibitor, as a sole approach to downregulate CDK1 activity weakened their conclusion. In contrast, we used multiangled approaches to show the inhibitory role of CDK1 in MDC1 foci formation. As the sustained MDC1-gH2AX interaction is required for consistent downstream DDR activation, decreased MDC1-gH2AX interaction in mitosis partially explains the incomplete DDR.
In summary, our findings provide new insights into the regulation of DDR in mitosis. In the context of unperturbed mitosis, inherent DSBs are unlikely to sever chromosomes, due to their supercondensed structure. We and others have shown that DSBs induced during mitosis, either by mitotic poisons or g-irradiation, are actively repaired in postmitotic cells, as shown by late-stage DDR protein foci staining (5, 6) . Thus, completion of mitosis is prioritized over DSB repair, which supports our previous findings that prolonged mitosis induces genomic instability. Human cells benefit from timely progression through mitosis rather than repair. To ensure this, a subgroup of MDC1 dissociate from gH2AX foci in a CDK1-dependent manner to promote normal metaphase-anaphase transition.
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